| Type | Title | Date Released | |
|---|---|---|---|
424B3 | UPDATE TO PRIOR PROSPECTUS | Offering amount: $24,400,000 | Shares: 17,851,599 | ||
8-K | AEON Biopharma Amends Two-Year Warrants to Reduce Exercise Price and Expects $6.2 Million in Gross Proceeds | ||
DEF 14A | Form DEF 14A | ||
8-K | Therapeutic Neurotoxin Developer Advances ABP-450 Biosimilar Strategy, Planning FDA Study Submission in Fourth Quarter 2026 | ||
PRE 14A | Form PRE 14A | ||
8-K | AEON Biopharma Receives Positive FDA Type 2b Feedback Clarifying Biosimilar Development Plan for ABP-450 | ||
SCHEDULE 13G | LYNCH TIMOTHY P (Filed by) | ||
4 | LYNCH TIMOTHY P (Reporting) | ||
3 | LYNCH TIMOTHY P (Reporting) | ||
10-Q | Form 10-Q | ||
8-K | AEON Biopharma Reports Second Quarter 2026 Financial Results and Corporate Update | ||
8-K | AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards |
